Project Grant K99AG097980
- The National Institute on Aging awarded Icahn School of Medicine at Mount Sinai $704,145 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop and apply computational methods for inferring the natural history of Alzheimer's disease from sparse longitudinal molecular and neuroimaging data. The recipient will develop an innovative approach that leverages temporal signal in sparse longitudinal datasets to reconstruct the timeline of Alzheimer's disease progression and...
- The National Institute on Aging awarded Icahn School of Medicine at Mount Sinai $230,388 on March 4, 2026, under the Aging Research program (CFDA 93.866) to dissect the role of the PICALM/EED locus on myeloid cells in Alzheimer's disease. The recipient will conduct research to understand how an Alzheimer's disease risk enhancer on chromosome 11 influences expression of two target genes—PICALM (phosphatidylinositol binding clathrin assembly protein) and EED (embryonic ectoderm development)—and to...
- The National Institute on Aging awarded Icahn School of Medicine at Mount Sinai $746,063 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate amyloid beta plaque formation and neuroinflammation in aging people with HIV. The award funds exploration of cell-specific transcriptional changes associated with early amyloid beta deposition in human brain, distinguishing compacted amyloid with early neuritic pathology from diffuse amyloid without neuritic change, and...
- The National Institute on Aging, a component of the Department of Health and Human Services National Institutes of Health, awarded $198,728 to The Rockefeller University on February 21, 2026, under the Aging Research program (CFDA 93.866) to identify cell type-specific RNA expression and regulatory changes in entorhinal cortex clinical samples of Alzheimer's disease. The funded work develops and applies a novel methodology called CLIP-FANS (crosslinking immunoprecipitation-fluorescence activated...
- The National Institute on Aging awarded The Research Foundation For The State University Of New York (operating as Stony Brook University) $454,937 on February 15, 2026, under the Aging Research program (CFDA 93.866) to investigate the regulatory landscape of neurodegeneration using single-cell spatial multiomics approaches. The research integrates chromatin accessibility and protein-level measurements to characterize how cells near Alzheimer's disease hallmarks—amyloid-beta and tau—regulate...
- The National Institute on Aging awarded the Translational Genomics Research Institute $123,066 on July 1, 2026, under the Aging Research program (CFDA 93.866) to identify molecular differences between Lewy body disease and Alzheimer's disease through multi-omics analysis. The recipient will characterize transcriptomic and genomic alterations in postmortem anterior cingulate cortex tissue from 607 neuropathologically defined cases, including those with Lewy body disease, Alzheimer's disease,...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded Icahn School of Medicine at Mount Sinai a Project Grant of $463,916 under the Aging Research program (CFDA 93.866) for the period September 1, 2025 through August 31, 2027. The award funds research to identify and characterize the "ankosome," a newly discovered cytoplasmic activation platform for caspase-2 (C2) that assembles in response to cytoskeletal injury. This exploratory research (R21 mechanism)...
- The National Institute on Aging, a component of the Department of Health and Human Services, awarded $397,689 to the Research Foundation of The City University of New York (doing business as RFCUNY - Advanced Science Research Center) on September 1, 2026, under the Aging Research program (CFDA 93.866) for Project Grant R01AG103127. The award funds research into pathway-specific vulnerability of dopamine-glutamate neurons in aging and memory. The research examines how dopamine neurons...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded Icahn School of Medicine at Mount Sinai a Project Grant of $2,129,396 under the Aging Research program (CFDA 93.866) on August 1, 2025, with completion targeted for July 31, 2027. This research grant supports the development and validation of novel adeno-associated virus (AAV) constructs designed to enable gene knockdown in follicle-stimulating hormone receptor (FSHR)-positive neurons within Alzheimer's...
- The National Institute on Aging, part of the Department of Health and Human Services, awarded $132,300 to The Trustees of Columbia University in the City of New York on July 15, 2026, under the Aging Research program (CFDA 93.866) to examine the relationship between job loss due to layoffs across working years and the risk of Alzheimer's disease and related dementias in mid-to-later life. The research leverages longitudinal data from three complementary datasets spanning the working years of the...
The National Institute on Aging awarded $133,110 to Icahn School of Medicine at Mount Sinai on September 5, 2026, under the Aging Research program (CFDA 93.866) for project K99AG097980. The recipient will integrate single-nucleus and spatial transcriptomics with machine-learning models to establish a comprehensive lifespan reference of the healthy human prefrontal cortex and identify Alzheimer's disease-specific deviations. During the K99 mentored phase, the work will harmonize single-nucleus RNA-sequencing data from the PsychAD Consortium and public resources spanning the first trimester through over 100 years to reconstruct cross-lineage pseudotime trajectories and pseudotime-aware intercellular communication networks. The recipient will also integrate publicly available 10X Visium datasets to define age-related spatial remodeling of cell types, gene-expression gradients, and neighborhood interactions. In the R00 independent phase, the recipient will generate new high-resolution Xenium 5K datasets spanning prenatal through aging stages to complete a lifespan-resolved spatial atlas, extend analyses to Alzheimer's disease by mapping disease-related divergence from healthy trajectories, and validate disrupted cellular niches and signaling networks. The mentored work occurs under the guidance of Panos Roussos, Guo-Cheng Yuan, and Alison Goate. Performance occurs in New York, NY 10029. The period of performance runs through August 31, 2028.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $133.1k | 9/3/26 |